Rationally designed viruses for use as vaccines or solid tumor therapies
Codagenix is a clinical stage synthetic biology company that uses software to recode the genomes of viruses, constructing live-attenuated vaccines or viruses to prevent viral infections or treat solid tumors. Codagenix’s recoded vaccine candidates are a perfect antigenic match to the target virus and induce a robust immune response to all viral antigens. For cancer, our nimble platform allows us to turn a virus into a potential oncolytic immuno-oncology therapies. Both programs rely on scalable, low-cost manufacturing.
RSV hospitalizations among adults 65+ no vaccine
Flu cases in 2017-18, current vaccines <37% effective
1 in 8
US women (about 12%) will develop invasive breast cancer during lifetime.
July 22, 2020
NIH Supports Codagenix’s Human Codon Deoptimized RSV Vaccine Via $2.2M Grant and a Renewed R&D Contract for Scale-up Manufacturing
Farmingdale, N.Y., July 22, 2020 – Codagenix, Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced the award of a $2.2 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the continued development of its human codon deoptimized […]Full Story
July 01, 2020
Codagenix Broadens Patent Protection for Codon-Deoptimized RSV Vaccine Candidates
Farmingdale, N.Y., July 1, 2020 – Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced the issuance of a patent for a vaccine focused on a codon-deoptimized respiratory syncytial viruses (RSV) vaccine. Codagenix currently holds the exclusive license to this patent. The issuance of US Patent No. 10,695,414 broadens […]Full Story